Castle Biosciences gains approval for dual listing on Nasdaq Texas

Castle Biosciences gains approval for dual listing on Nasdaq Texas
Castle adds Nasdaq Texas listing

Castle Biosciences has received approval to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas.

The company will maintain its primary listing on The Nasdaq Global Market, while investors can expect Castle Biosciences shares to begin trading on Nasdaq Texas in the near future. This move broadens Castle Biosciences' market presence and could offer increased liquidity for its stock as the new exchange ramps up operations.

Castle Biosciences recently reported Q2 2026 revenue of $103.5 million as its core test volume increased 32 percent over the prior year period, according to company filings. The company’s growth has also been shaped by bioscience alliances in Phoenix, as detailed by its COO Kristen Oelschlager in previous commentary. These developments provide additional context for Castle Biosciences' expanding market activity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.